Skip to main content
Erschienen in: Journal of Nuclear Cardiology 4/2019

01.08.2019 | Editorial

Could FDG-PET imaging play a role in the detection of progressing atherosclerosis in HIV-infected patients?

verfasst von: Nidaa Mikail, MD, Mathieu Sinigaglia, MD, Fabien Hyafil, MD, PhD

Erschienen in: Journal of Nuclear Cardiology | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Important progresses in the management of patients with human immunodeficiency virus, in particular the advent of new anti-retroviral therapies (ART), have turned this rapidly fatal condition into a controllable chronic disease with a life expectancy that approaches the one from the general population. Cardiovascular diseases have now become one of the leading causes of non-HIV-related mortality in this population. Several factors including the presence of HIV in the vascular wall and the development of dyslipidemia and alteration in body fat distribution under ART might play a role the progression of atherosclerosis in HIV-infected patients. The use of imaging biomarkers may help to identify the factors associated with an increased risk of cardiovascular events and select high-risk patients who will benefit the most from the early implementation of preventive treatments.
Literatur
1.
Zurück zum Zitat Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med 2006;145:397-406.CrossRefPubMed Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med 2006;145:397-406.CrossRefPubMed
2.
Zurück zum Zitat Vandenhende MA, Roussillon C, Henard S, Morlat P, Oksenhendler E, Aumaitre H, et al. Cancer-Related causes of death among HIV-infected patients in France in 2010: evolution since 2000. PLoS ONE 2015;10:e0129550.CrossRefPubMedPubMedCentral Vandenhende MA, Roussillon C, Henard S, Morlat P, Oksenhendler E, Aumaitre H, et al. Cancer-Related causes of death among HIV-infected patients in France in 2010: evolution since 2000. PLoS ONE 2015;10:e0129550.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Friis-Møller N, Reiss P, Sabin CA, Weber R, Monforte Ad, El-Sadr W, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356:1723-35.CrossRefPubMed Friis-Møller N, Reiss P, Sabin CA, Weber R, Monforte Ad, El-Sadr W, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356:1723-35.CrossRefPubMed
4.
Zurück zum Zitat Freiberg MS, Chang CC, Kuller LH, Skanderson M, Lowy E, Kraemer KL, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 2013;173:614-22.CrossRefPubMedPubMedCentral Freiberg MS, Chang CC, Kuller LH, Skanderson M, Lowy E, Kraemer KL, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 2013;173:614-22.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Currier JS, Lundgren JD, Carr A, Klein D, Sabin CA, Sax PE, et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation 2008;118:e29-35.CrossRefPubMedPubMedCentral Currier JS, Lundgren JD, Carr A, Klein D, Sabin CA, Sax PE, et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation 2008;118:e29-35.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Mujawar Z, Rose H, Morrow MP, Pushkarsky T, Dubrovsky L, Mukhamedova N, et al. Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol 2006;4:e365.CrossRefPubMedPubMedCentral Mujawar Z, Rose H, Morrow MP, Pushkarsky T, Dubrovsky L, Mukhamedova N, et al. Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol 2006;4:e365.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Triant VA, Meigs JB, Grinspoon SK. Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr 2009;51:268-73.CrossRefPubMedPubMedCentral Triant VA, Meigs JB, Grinspoon SK. Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr 2009;51:268-73.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008;5:e203.CrossRefPubMedPubMedCentral Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008;5:e203.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Dressman J, Kincer J, Matveev SV, et al. HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages. J Clin Invest 2003;111:389-97.CrossRefPubMedPubMedCentral Dressman J, Kincer J, Matveev SV, et al. HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages. J Clin Invest 2003;111:389-97.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Koppel K, Bratt G, Schulman S, Bylund H, Sandstrom E. Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002;29:441-9.CrossRefPubMed Koppel K, Bratt G, Schulman S, Bylund H, Sandstrom E. Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002;29:441-9.CrossRefPubMed
12.
Zurück zum Zitat El-Sadr WM, Lundgren J, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4 + count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283-96.CrossRefPubMed El-Sadr WM, Lundgren J, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4 + count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283-96.CrossRefPubMed
13.
Zurück zum Zitat Tawakol A, Migrino RQ, Bashian GG, Bedri S, Vermylen D, Cury RC, et al. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol 2006;48:1818-24.CrossRefPubMed Tawakol A, Migrino RQ, Bashian GG, Bedri S, Vermylen D, Cury RC, et al. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol 2006;48:1818-24.CrossRefPubMed
14.
Zurück zum Zitat Hetterich H, Rominger A, Walter L, Habs M, Volpers S, Hacker M, et al. Natural history of atherosclerotic disease progression as assessed by (18)F-FDG PET/CT. Int J Cardiovasc Imaging 2016;32(1):49-59.CrossRefPubMed Hetterich H, Rominger A, Walter L, Habs M, Volpers S, Hacker M, et al. Natural history of atherosclerotic disease progression as assessed by (18)F-FDG PET/CT. Int J Cardiovasc Imaging 2016;32(1):49-59.CrossRefPubMed
15.
Zurück zum Zitat Rominger A, Saam T, Wolpers S, Cyran CC, Schmidt M, Foerster S, et al. 18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease. J Nucl Med 2009;50:1611-20.CrossRefPubMed Rominger A, Saam T, Wolpers S, Cyran CC, Schmidt M, Foerster S, et al. 18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease. J Nucl Med 2009;50:1611-20.CrossRefPubMed
16.
Zurück zum Zitat Figueroa AL, Abdelbaky A, Truong QA, Corsini E, MacNabb MH, Lavender ZR, et al. Measurement of arterial activity on routine FDG PET/CT images improves prediction of risk of future CV events. JACC Cardiovasc Imaging 2013;6:1250-9.CrossRefPubMed Figueroa AL, Abdelbaky A, Truong QA, Corsini E, MacNabb MH, Lavender ZR, et al. Measurement of arterial activity on routine FDG PET/CT images improves prediction of risk of future CV events. JACC Cardiovasc Imaging 2013;6:1250-9.CrossRefPubMed
17.
Zurück zum Zitat Moon SH, Cho YS, Noh TS, Choi JY, Kim BT, Lee KH. Carotid FDG Uptake improves prediction of future cardiovascular events in asymptomatic individuals. JACC Cardiovasc Imaging 2015;8:949-56.CrossRefPubMed Moon SH, Cho YS, Noh TS, Choi JY, Kim BT, Lee KH. Carotid FDG Uptake improves prediction of future cardiovascular events in asymptomatic individuals. JACC Cardiovasc Imaging 2015;8:949-56.CrossRefPubMed
18.
Zurück zum Zitat Rudd JH, Myers KS, Bansilal S, Machac J, Pinto CA, Tong C, et al. Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J Nucl Med 2008;49:871-8.CrossRefPubMed Rudd JH, Myers KS, Bansilal S, Machac J, Pinto CA, Tong C, et al. Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J Nucl Med 2008;49:871-8.CrossRefPubMed
20.
Zurück zum Zitat Huet P, Burg S, Le Guludec D, Hyafil F, Buvat I. Variability and uncertainty of 18F-FDG PET imaging protocols for assessing inflammation in atherosclerosis: suggestions for improvement. J Nucl Med 2015;56:552-9.CrossRefPubMed Huet P, Burg S, Le Guludec D, Hyafil F, Buvat I. Variability and uncertainty of 18F-FDG PET imaging protocols for assessing inflammation in atherosclerosis: suggestions for improvement. J Nucl Med 2015;56:552-9.CrossRefPubMed
21.
Zurück zum Zitat Burg S, Dupas A, Stute S, Dieudonné A, Huet P, Le Guludec D, et al. Partial volume effect estimation and correction in the aortic vascular wall in PET imaging. Phys Med Biol 2013;58:7527-42.CrossRefPubMed Burg S, Dupas A, Stute S, Dieudonné A, Huet P, Le Guludec D, et al. Partial volume effect estimation and correction in the aortic vascular wall in PET imaging. Phys Med Biol 2013;58:7527-42.CrossRefPubMed
22.
Zurück zum Zitat Bucerius J, Hyafil F, Verberne HJ, Slart RH, Lindner O, Sciagra R, et al. Position paper of the Cardiovascular Committee of the European Association of Nuclear Medicine (EANM) on PET imaging of atherosclerosis. Eur J Nucl Med Mol Imaging 2016;43:780-92.CrossRefPubMed Bucerius J, Hyafil F, Verberne HJ, Slart RH, Lindner O, Sciagra R, et al. Position paper of the Cardiovascular Committee of the European Association of Nuclear Medicine (EANM) on PET imaging of atherosclerosis. Eur J Nucl Med Mol Imaging 2016;43:780-92.CrossRefPubMed
Metadaten
Titel
Could FDG-PET imaging play a role in the detection of progressing atherosclerosis in HIV-infected patients?
verfasst von
Nidaa Mikail, MD
Mathieu Sinigaglia, MD
Fabien Hyafil, MD, PhD
Publikationsdatum
01.08.2019
Verlag
Springer International Publishing
Erschienen in
Journal of Nuclear Cardiology / Ausgabe 4/2019
Print ISSN: 1071-3581
Elektronische ISSN: 1532-6551
DOI
https://doi.org/10.1007/s12350-018-1247-2

Weitere Artikel der Ausgabe 4/2019

Journal of Nuclear Cardiology 4/2019 Zur Ausgabe

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.